COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA

被引：10
|
作者：
Daacke, I [1 ]
Kandaswamy, P. [2 ]
Tebboth, A. [3 ]
Kansal, A. [4 ]
Reifsnider, O. [4 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim UK, Bracknell, Berks, England
[4] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1876
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB46
引用
收藏
页码：A673 / A673
页数：1
相关论文
共 50 条
  • [41] Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    DIABETES, 2020, 69
  • [42] Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians
    Naing, Soe
    Poliyedath, Anupama
    Khandelwal, Stutee
    Sigala, Teresa
    POSTGRADUATE MEDICINE, 2016, 128 (08) : 822 - 827
  • [43] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S325 - S326
  • [44] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [45] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A69 - A69
  • [46] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
  • [47] Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
    Cooper, Mark E.
    Inzucchi, Silvio E.
    Zinman, Bernard
    Hantel, Stefan
    von Eynatten, Maximilian
    Wanner, Christoph
    Koitka-Weber, Audrey
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (05) : 713 - 715
  • [48] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [49] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, A.
    Inzucchi, S. E.
    Testani, J.
    Ofstad, A. P.
    Fitchett, D.
    Mattheus, M.
    Verma, S.
    Zannad, F.
    Wanner, C.
    Kraus, B. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 175 - 175
  • [50] COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) 10 MG AND 25 MG ADMINISTERED AS AN AD-ON TO METFORMIN COMPARED TO OTHER SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2IS) FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK
    Aguiar-Ibanez, R.
    Palencia, R.
    Kandaswamy, P.
    Li, L.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A351
12345